HIGHLIGHTS
Growth of Lundbeck's strategic brands accelerates further growing 30% (+19% in local currencies) in the first nine months of 2022 thereby reaching
- Brintellix®/Trintellix®: +24% reported to
DKK 3,177 million (+15% in local currencies) -
Rexulti®/Rxulti®: +33% reported to
DKK 2,817 million (+19% in local currencies) -
Abilify Maintena®: +20% reported to
DKK 2,164 million (+13% in local currencies) -
Vyepti®: +105% reported to
DKK 672 million (+82% in local currencies)
All markets contribute to revenue momentum with total revenue growing 11% (+6% in local currencies to
United States : +19% reported toDKK 6,585 million (+6% in local currencies)-
International Markets: +13% reported to
DKK 4,023 million (+5% in local currencies) Europe : +11% reported toDKK 3,154 million (+11% in local currencies)
Currency favorability on product sales partially offset by negative hedging effects of
- EBITDA: +14% reported to
DKK 3,753 million -
EBIT: +22% reported to
DKK 2,449 million -
Core EBIT: +13% reported to
DKK 3,372 million -
EPS: +22% reported to
DKK 1.62 -
Core EPS: +24% reported to
DKK 2.61
In connection with the financial report, Lundbeck's President and CEO,
"Reporting 11% growth in our total revenues with our strategic brands themselves growing 30% underlines the strong momentum in the Lundbeck business. Our R&D transformation is advancing strongly. Lundbeck has substantial growth ahead and we will invest behind those opportunities."
2022 GUIDANCE
Guidance in reported currency for 2022 updated ahead of this quarterly release to account for strong organic revenue momentum in strategic brands and appreciation of Lundbeck's main currencies while considering generally increased activity level and concurrent investments in acceleration and global launch of Vyepti
- Revenue expected at
DKK 17.9 - 18.2 billion -
EBITDA expected at
DKK 4.4 - 4.6 billion -
Core EBIT expected at
DKK 3.9 - 4.1 billion -
EBIT expected at
DKK 2.6 - 2.8 billion
Key figures:
DKK million | 9M 2022 | 9M 2021 | Growth | Q3 2022 | Q3. 2021 | Growth |
Core Revenue1 | 13,566 | 12,246 | 11% | 4,719 | 4,013 | 18% |
Core EBIT1 | 3,372 | 2,973 | 13% | 1,299 | 826 | 57% |
Core EPS1,2 | 2.61 | 2.10 | 24% | |||
Core EBIT-margin1 | 24.9% | 24.3% | 27.5% | 20.6% | ||
Reported Revenue | 13,566 | 12,246 | 11% | 4,719 | 4,013 | 18% |
Reported EBIT | 2,449 | 2,004 | 22% | 952 | 526 | 81% |
Reported EPS2 | 1.62 | 1.33 | 22% | 0.69 | 0.32 | 116% |
Reported EBIT-margin | 18.1% | 16.4% | 20.2% | 13.1% |
1 For definition of the measures "Core Revenue", "Core EBIT", "Core EPS" and "Core EBIT-margin", see note 4 Core reporting.
2 The calculation of EPS is based on a share denomination of
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/lundbeck-s-sales-increased-by-11---6--in-local-currencies--to-dkk-13-6-billion-in-the-first-nine-mon,c3663982
https://mb.cision.com/Main/18215/3663982/1658450.pdf
(c) 2022 Cision. All rights reserved., source